BR0202439A - Complexo, método para prolongar o tempo que o ocif ou um seu análogo ou variante fica retido na corrente sang ìnea, composição farmacêutica, uso de um complexo, e, método para a preparação de um complexo - Google Patents

Complexo, método para prolongar o tempo que o ocif ou um seu análogo ou variante fica retido na corrente sang ìnea, composição farmacêutica, uso de um complexo, e, método para a preparação de um complexo

Info

Publication number
BR0202439A
BR0202439A BR0202439-0A BR0202439A BR0202439A BR 0202439 A BR0202439 A BR 0202439A BR 0202439 A BR0202439 A BR 0202439A BR 0202439 A BR0202439 A BR 0202439A
Authority
BR
Brazil
Prior art keywords
complex
ocif
variant
retained
preparing
Prior art date
Application number
BR0202439-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Shinichi Yamamoto
Junichi Okada
Atsushi Kurihara
Taku Numazawa
Junichi Kondo
Eisuke Tsuda
Shinichi Mochizuki
Hirotaka Nishi
Hideki Miyazaki
Original Assignee
Sankio Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankio Company Ltd filed Critical Sankio Company Ltd
Publication of BR0202439A publication Critical patent/BR0202439A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0202439-0A 2001-06-29 2002-06-28 Complexo, método para prolongar o tempo que o ocif ou um seu análogo ou variante fica retido na corrente sang ìnea, composição farmacêutica, uso de um complexo, e, método para a preparação de um complexo BR0202439A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001198985 2001-06-29

Publications (1)

Publication Number Publication Date
BR0202439A true BR0202439A (pt) 2003-06-10

Family

ID=19036337

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0202439-0A BR0202439A (pt) 2001-06-29 2002-06-28 Complexo, método para prolongar o tempo que o ocif ou um seu análogo ou variante fica retido na corrente sang ìnea, composição farmacêutica, uso de um complexo, e, método para a preparação de um complexo

Country Status (22)

Country Link
US (3) US20030045456A1 (enExample)
EP (1) EP1270015A3 (enExample)
KR (1) KR20030003124A (enExample)
CN (1) CN1442201A (enExample)
AR (1) AR034716A1 (enExample)
AU (1) AU783126B2 (enExample)
BR (1) BR0202439A (enExample)
CA (1) CA2392383A1 (enExample)
CO (1) CO5390084A1 (enExample)
CZ (1) CZ20022231A3 (enExample)
HK (1) HK1048762A1 (enExample)
HU (1) HUP0202119A2 (enExample)
IL (1) IL150448A0 (enExample)
MX (1) MXPA02006511A (enExample)
NO (1) NO20023144L (enExample)
PA (1) PA8549401A1 (enExample)
PE (1) PE20030254A1 (enExample)
PL (1) PL354799A1 (enExample)
RU (1) RU2232594C2 (enExample)
SG (1) SG98059A1 (enExample)
SK (1) SK9492002A3 (enExample)
ZA (1) ZA200205164B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO2000024416A1 (en) 1998-10-28 2000-05-04 Snow Brand Milk Products Co., Ltd. Remedies for bone metabolic errors
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
EP1482978A1 (en) * 2002-03-01 2004-12-08 Sankyo Company, Limited Pharmaceutical composition comprising osteoclastogenesis inhibitory factor
AU2003240754B2 (en) 2002-04-10 2009-02-26 Merck Serono Sa Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
US7585840B2 (en) * 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
AU2003242265A1 (en) * 2002-06-07 2003-12-22 Sankyo Company, Limited Combined effects of therapeutic or preventive agent composition for bone breakage
RU2323227C2 (ru) * 2003-03-24 2008-04-27 Санкио Компани Лимитед Полимерные модификаторы и фармацевтические композиции
KR100840830B1 (ko) * 2006-09-03 2008-06-23 재단법인서울대학교산학협력재단 고분자 히알루론산을 포함하는 골흡수 저해용 조성물
RU2370271C2 (ru) * 2006-11-22 2009-10-20 Государственное учреждение гематологический научный центр Российской академии медицинских наук (ГУ ГНЦ РАМН) Способ обнаружения комплексов между гепаринами и поликатионами
ITMI20121316A1 (it) * 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
CN115594776B (zh) * 2022-09-19 2024-03-15 山东大学 一种ROS响应性聚合物Mal-PHB-Dextran及细胞背包载药系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US45456A (en) * 1864-12-13 Improved apparatus for carbureting air
US216297A (en) * 1879-06-10 Improvement in ironing-stands
US139325A (en) * 1873-05-27 Improvement in carriage-springs
US181418A (en) * 1876-08-22 Improvement in gas apparatus
US4207A (en) * 1845-09-27 lewis
US31725A (en) * 1861-03-19 Improvement in cultivators
TW318142B (enExample) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
DE69834719D1 (de) * 1997-09-24 2006-07-06 Sankyo Co Methode zur diagnose von abnormalem knochenstoffwechsel
ATE230752T1 (de) * 1998-06-15 2003-01-15 Takeda Chemical Industries Ltd Thienodipyridinderivate, ihre herstellung und verwendung
WO2000024416A1 (en) * 1998-10-28 2000-05-04 Snow Brand Milk Products Co., Ltd. Remedies for bone metabolic errors
KR20010085996A (ko) * 1999-09-03 2001-09-07 스티븐 엠. 오드레 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
IL155097A0 (en) * 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
EP1482978A1 (en) * 2002-03-01 2004-12-08 Sankyo Company, Limited Pharmaceutical composition comprising osteoclastogenesis inhibitory factor

Also Published As

Publication number Publication date
SG98059A1 (en) 2003-08-20
IL150448A0 (en) 2002-12-01
SK9492002A3 (en) 2003-02-04
CZ20022231A3 (cs) 2003-02-12
NO20023144L (no) 2002-12-30
AU783126B2 (en) 2005-09-29
PA8549401A1 (es) 2003-07-28
HU0202119D0 (enExample) 2002-08-28
CN1442201A (zh) 2003-09-17
ZA200205164B (en) 2003-03-24
US20030045456A1 (en) 2003-03-06
RU2002117385A (ru) 2004-01-27
HK1048762A1 (en) 2003-04-17
US20030139325A1 (en) 2003-07-24
CO5390084A1 (es) 2004-04-30
KR20030003124A (ko) 2003-01-09
RU2232594C2 (ru) 2004-07-20
MXPA02006511A (es) 2004-08-11
CA2392383A1 (en) 2002-12-29
NO20023144D0 (no) 2002-06-28
PL354799A1 (en) 2002-12-30
US20060084595A1 (en) 2006-04-20
HUP0202119A2 (hu) 2003-04-28
PE20030254A1 (es) 2003-03-19
AR034716A1 (es) 2004-03-17
AU5071902A (en) 2003-01-02
EP1270015A3 (en) 2004-02-25
EP1270015A2 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
Ornetti et al. Does platelet-rich plasma have a role in the treatment of osteoarthritis?
Ueno et al. The effects of prostaglandin E2 in rapidly growing rats: depressed longitudinal and radial growth and increased metaphyseal hard tissue mass
JP5639604B2 (ja) 炎症を抑制するための医薬組成物
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR9713141A (pt) Composição farmcêutica processo e kit para o tratamento ou a prevenção de um quadro fisiológico asociado com um distúrbio isquêmico relacionado com trombose e um paciente, uso de quantidades farmaceuticamente efetivas de um composto com atividade anti-xa e de um composto antagonista de agregação de plaquetas, produto contendo estes compostos, e, uso destes compostos.
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
BR9914585A (pt) Formulação aquosa de insulina, preparação de insulina, e, método de tratamento de diabetes do tipo i ou do tipo ii
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BR0211665A (pt) Composto, composição farmacêutica, método para a redução de glicose, método para a prevenção ou para tratamento de doenças, medicamento para a redução de glicose, medicamento para a prevenção ou para o tratamento de doenças, uso do composto, da composição farmacêutica e do medicamento e processo para a preparação do composto
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
SE8802569D0 (sv) Improvements in or relation to somatostatins
BR0110837A (pt) Quimioterapia de combinação
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
BR9808008A (pt) Processo para o tratamento anticoagulante e/ou antitrombótico de um ser humano ou outro paciente animal de sangue quente, usos de um oligossacarìdeo sulfatado e na fabricação de um medicamento, e, composição farmacêutica ou veterinária para tratamento anticoagulante e/ou antitrombótico.
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
EP1050301A4 (en) Medicinal compositions
DK0536363T3 (da) Hidtil ukendte heparinderivater og fremgangsmåde til fremstilling deraf
EP1611893B1 (en) Remedy for nerve damage
BR0309595A (pt) Injeção produzida a partir de ixeris sonchifolia hance para o tratamento de doenças vasculares cardiocerebrais e doenças de fundo, e método para a produção da mesma
RU2005135428A (ru) Поглощение макромолекул
RU2216548C2 (ru) Смесь линейных олигосахаридов, полученная из дерматансульфата, фармацевтическая композиция, обладающая антитромботическим действием, и способ лечения
BR9914834A (pt) Agente de tratamento de patobolismo ósseo, e, método para intensificar a atividade de fator inibidor de osteoclastogênese
DK0630651T3 (da) Halvfast farmaceutisk middel og fremgangsmåde til fremstilling heraf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1980 DE 16/12/2008.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/61 (2017.01), A61P 19/00 (2006.01)